Prostate cancer around the world. An overview

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 6, 2010, Pages 663-667

  Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

HUMAN; INCIDENCE; MALE; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNITED STATES;

EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WORLD HEALTH;

EID: 78149377824     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.12.013     Document Type: Review

References (17)

1. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 325:963-965.
2. Bouchardy C., Fioretta G., Rapiti E., et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008, 123:421-429.
3. Etzioni R., Tsodikov A., Mariotto A., et al. Quantifying the role of PSA screening in the U.S. prostate cancer mortality decline. Cancer Causes Control 2008, 19:175-181.
4. Platz E.A., Rimm E.B., Willett W.C., et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000, 92:2009-2017.
5. Accessed March 24, 2010. http://www.clip-iarc.fr.
6. Sim H.G., Cheng C.W.S. Changing demography of prostate cancer in Asia. Eur J Cancer 2005, 41:834-845.
7. Ito K., Raaijmakers R., Roobol M., et al. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Cancer 2005, 103:242-250.
8. Ku J.H. Race-specific reference ranges of serum prostate-specific antigen levels in countries with a low incidence of prostate cancer. BJU Int 2006, 97:69-72.
9. Kranse R., Beemsterboer P.M.M., Rietbergen J.B.W., et al. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). The Prostate 1999, 39:316-322.
10. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 2006, 296:2329-2335.
11. Schröder F.H., van den Bergh R.C., Wolters T., et al. Eleven-year outcome of patients with prostate cancer diagnosed during screening after initial negative sextant biopsies. Eur Urol 2010, 57:256-266.
12. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328. ERSPC investigators.
13. Andriole G.L., Crawford E.D., Grubb R.L., et al. PLCO Project Team Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
14. Parker C., Emberton M. Screening for prostate cancer appears to work, but at what cost?. BJU Int 2009, 104:290-292.
15. Grubb R.L., Pinsky P.F., Greenlee R.T., et al. Prostate cancer screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008, 102:1524-1530.
16. Cuzick J., Edwards R., Segnan N. Adjusting for noncompliance and contamination in randomized clinical trials. Stat Med 1997, 16:1017-1029.
17. Roobol M.J., Kerkhof M., Schröder F.H., et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for non-attendance and contamination in the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009, 56:584-591.